BCA
PDLI

Bray Capital Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Bray Capital Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,859
Closed -$4K – 346
2019
Q3 		$4K Hold
1,859
– – ﹤0.01% 316
2019
Q2 		$6K Hold
1,859
– – ﹤0.01% 301
2019
Q1 		$7K Hold
1,859
– – ﹤0.01% 286
2018
Q4 		$5K Hold
1,859
– – ﹤0.01% 304
2018
Q3 		$5K Buy
+1,859
New +$4.56K ﹤0.01% 318

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return
Brandes Investment Partners
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bray Capital Advisors's PDLI Position: Q4 2019 in Review

Bray Capital Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2019, closing a stake of 1,859 shares — an estimated $4K sold.

Bray Capital Advisors first reported a position in PDLI in Q3 2018 and held it in 5 quarters. The position peaked at $7K in Q1 2019. 150 funds tracked by Wall St. Rank hold PDLI as of Q4 2019.

  • Bray Capital Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2019 after selling out during the quarter.
  • Bray Capital Advisors sold 1,859 PDL BioPharma, Inc. shares in Q4 2019, an estimated $4K.
  • Bray Capital Advisors first reported a position in PDL BioPharma, Inc. in Q3 2018 and held it in 5 quarters.
  • Bray Capital Advisors's PDL BioPharma, Inc. position peaked at $7K in Q1 2019.
  • 150 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2019.

Based on Bray Capital Advisors's 13F filing for Q4 2019, filed 31 Jan 2020.